跳至主要内容
临床试验/EUCTR2019-001660-30-IT
EUCTR2019-001660-30-IT进行中(未招募)1 期

A prospective, observer-masked, randomized clinical trial to investigate and compare the clinical efficacy of chloroprocaine 3% gel and tetracaine 0.5% eye drop as topical anesthetics in phacoemulsification. - CHL.3/01-2019/M

SINTETICA S.A.0 个研究点目标入组 342 人开始时间: 2020年7月30日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
342

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Signed and dated informed consent
  • 2.Male or female aged > = 18 years
  • 3.Senile or pre-senile cataract
  • 4.Scheduled to undergo cataract surgery in a single eye at a time (clear corneal self-sealing incisions - phacoemulsification – foldable intra-ocular lens surgery with injector)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 228
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 114

排除标准

  • Ophthalmic exclusion criteria
  • - Surgical conditions in the eye to be operated:
  • 1.Combined surgery
  • 2.Previous intraocular surgery
  • 3.Previous corneal refractive surgeries less than 6 months before screening
  • - Non-surgical conditions in the eye to be operated:
  • 4.Non Senile or non pre-senile cataract (e.g.: traumatic, pathological or congenital cataract)
  • 5.Pupillary abnormalities (irregular, etc.)
  • 6.Iris synechiae
  • 7.Eye movement disorder (nystagmus, etc.)
  • 8.Dacryocystitis and all other pathologies of tears drainage system
  • 9.History of Inflammatory ocular disease (Iritis, uveitis, herpetic keratitis)
  • 10.Corneal, epithelial, stromal or endothelial, residual or evolutionary disease (including corneal ulceration and superficial punctuate keratitis)
  • 11.History of ocular traumatism, infection or inflammation within the last 3 months
  • 12.Pseudo-exfoliation, exfoliative syndrome
  • 13.Prior intravitreal injections within 7 days of the surgery
  • 14. IOP over 25mmHg under treatment
  • - Ophthalmic conditions in the contra-lateral eye:
  • 15. Best corrected visual acuity < 1/10
  • 16. Patient already included in the study for phakoexeresis
  • 17. History of ophthalmic surgical complication (cystoid macular oedema, etc.)
  • - Systemic/non ophthalmicexclusioncriteria
  • --General history:
  • 18. Diabetesmellitus
  • 19. Surdity
  • 20. Pakinsondisease
  • 21. Excessive anxiety
  • 22. Any other medical or surgical history, disorder or disease such as acute or chronic severe organic disease: hepatic, endocrine neoplasic, hematological diseases, severe psychiatric illness, relevant cardiovascular abnormalities (such as unstable angina, bradycardia, atrial fibrillation,uncontrolled hypertension: systolic blood pressure over 140 mm Hg, diastolic blood pressure over 90 mmHg) and/or any complicating factor or structural abnormality judged by the investigator to be incompatible with the study.
  • --Allergic history:
  • 23. Known hypersensitivity to sulfonamides products or any of the components of the study medications or to test products Specific exclusion criteria for women
  • 24. Pregnancy (positive pregnancy test), lactation
  • 25. Women of childbearing potential without an acceptable effective method of contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant) until end of the study participation
  • 26. Women not hysterectomized, not menopaused nor surgically sterilized.
  • - Exclusion criteria related to general conditions
  • 27. Inability of patient and/or relatives to understand the study procedures and thus inability to give informed consent
  • 28. Non-compliant patient and/or relatives (e.g. not willing to attend the follow-up visits, way of life interfering with compliance)
  • 29. Participation in anotherclinicalstudy
  • 30. Already included once in this study
  • 31. Ward of court
  • 32. Patient not covered by the Social Security

研究者

相似试验

进行中(未招募)
1 期
Study to evaluate and compare the efficacy of local anesthetics Chloroprocaine 3% gel and Tetracaine 0.5% eye drops in cataract surgery.
EUCTR2019-001660-30-SKSintetica S.A.342
已完成
不适用
Effectiveness of proteolytic enzymes in controlling the post operative sequelae of surgical third molar disimpactions
CTRI/2017/10/010076Dr Chalakuzhy Paul Mathai90
进行中(未招募)
1 期
Prospective, blind-observer, randomised clinical study to investigate and compare the efficacy of intrathecal plain solutions containing Chloroprocaine 1% (50 mg) versus Bupivacaine 0.5% (10mg)Patients undergoing elective short duration (<40 min) low abdominal (in gynaecological and urological disciplines) or lower limbs (no more than 1/3 of cases) surgery.MedDRA version: 9.1Level: LLTClassification code 10030858Term: Operation NOS
EUCTR2007-000968-25-DESintetica SA
进行中(未招募)
不适用
Prospective, blind observer, randomised clinical study to investigate and compare the efficacy of intrathecal plain solutions containing Chloroprocaine 1% (50 mg) versus Bupivacaine 0.5% (10 mg) - NDpatients undergoing elective short-duration (< 40 min) in low abdominal (gynaecology and urology disciplines) or lower limbs (no more than 1/3 of cases) surgery under spinal anaesthesia.MedDRA version: 9.1Level: LLTClassification code 10041536Term: Spinal anaesthesia
EUCTR2007-000968-25-ITSINTETICA ITALIA S.R.L.120
进行中(未招募)
不适用
A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.
EUCTR2008-006265-93-SESt Eriks Eye Hospital60